Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells 50,906 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) insider Alane Barnes sold 50,906 shares of BioCryst Pharmaceuticals stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $7.21, for a total value of $367,032.26. Following the completion of the transaction, the insider owned 365,246 shares of the company's stock, valued at $2,633,423.66. The trade was a 12.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

BioCryst Pharmaceuticals Stock Up 9.6%

BioCryst Pharmaceuticals stock traded up $0.69 during midday trading on Wednesday, reaching $7.85. The company's stock had a trading volume of 7,602,203 shares, compared to its average volume of 4,026,871. The business has a 50-day simple moving average of $7.12 and a 200-day simple moving average of $8.38. The company has a market cap of $1.65 billion, a P/E ratio of -157.00 and a beta of 0.91. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.00 and a fifty-two week high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The firm had revenue of $159.40 million for the quarter, compared to analyst estimates of $162.91 million. During the same period last year, the firm earned ($0.07) EPS. The company's quarterly revenue was up 36.1% on a year-over-year basis. As a group, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on BCRX shares. Weiss Ratings reissued a "sell (e+)" rating on shares of BioCryst Pharmaceuticals in a report on Tuesday. Needham & Company LLC dropped their price objective on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, November 4th. Evercore ISI restated an "in-line" rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Citizens Jmp reduced their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a "market outperform" rating on the stock in a report on Wednesday, November 5th. Finally, JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the stock a "market outperform" rating in a research report on Wednesday, October 15th. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $19.33.

View Our Latest Research Report on BioCryst Pharmaceuticals

Institutional Trading of BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Allianz Asset Management GmbH raised its stake in BioCryst Pharmaceuticals by 9.6% during the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after purchasing an additional 1,200 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH grew its position in BioCryst Pharmaceuticals by 7.7% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,992 shares of the biotechnology company's stock worth $161,000 after acquiring an additional 1,288 shares in the last quarter. Royal Bank of Canada increased its position in BioCryst Pharmaceuticals by 2.4% during the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock worth $476,000 after buying an additional 1,458 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of BioCryst Pharmaceuticals by 7.4% in the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company's stock valued at $198,000 after acquiring an additional 1,527 shares in the last quarter. Finally, Main Management ETF Advisors LLC boosted its holdings in BioCryst Pharmaceuticals by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 112,128 shares of the biotechnology company's stock valued at $1,005,000 after acquiring an additional 1,824 shares during the period. 85.88% of the stock is owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Stories

• Five stocks we like better than BioCryst Pharmaceuticals
• Mastering Discipline: Overcoming Emotional Challenges In Trading
• 3 Stocks Poised to Benefit From Google’s AI Breakthough
• What Investors Need to Know to Beat the Market
• Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026
• What is the Dogs of the Dow Strategy? Overview and Examples
• 3 Stocks You’ll Wish You Bought Before 2026

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in BioCryst Pharmaceuticals Right Now?

Before you consider BioCryst Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.

While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here